Mylan NV
www.mylan.com
Latest From Mylan NV
Finance Watch: Moderna Launches Biggest Biopharma IPO Ever As US Market Resets Expectations
Public Company Edition: Moderna's $604m IPO launches as the US stock market is in decline and public biotechs are doing especially poorly. Also, as Shire acquisition closing moves near, Takeda firms up additional financing; and Global Blood, Theravance, Amarin capitalize on good news.
Biosimilar Litigation Settlement Score Card: Genentech-Pfizer Herceptin Agreement Is 10th Deal
Genentech inks second settlement of trastuzumab biosimilar litigation; suits ongoing against Amgen, Celltrion/Teva, and Samsung with joint claim construction proceedings.
Humira Biosimilars Face Complex Asia Outlook As Launches Edge Closer
The Asia Pacific region presents large potential opportunities for the development of biosimilar versions of big-selling original biologics as these come out of protection in the major markets. However the regulatory, reimbursement and commercial situation varies greatly country-by-country, presenting a complex mix of factors affecting the overall market outlook for these up and coming biosimilar products.
Humira Biosimilars Face Complex Asia Outlook As Launches Edge Closer
The Asia Pacific region presents large potential opportunities for the development of biosimilar versions of big-selling original biologics as these come out of protection in the major markets. However the regulatory, reimbursement and commercial situation varies greatly country-by-country, presenting a complex mix of factors affecting the overall market outlook for these up and coming biosimilar products.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Transdermal
- Generic Drugs
-
Drug Delivery
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Mylan Laboratories Inc.
- Mylan Inc.
- Ownership
- Public
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
UK
-
UK
-
Western Europe
-
Europe
- Parent & Subsidiaries
-
Mylan NV
- Agila Specialties Pvt. Ltd.
- Alphapharm Pty. Ltd.
- Dow Hickam Pharmaceuticals
- Meda AB
- Merck Generics Group
- Mylan Bertek Pharmaceuticals Inc.
- Mylan Institutional
- Mylan Laboratories Ltd.
- Mylan Pharmaceuticals Inc.
- Mylan Pharmaceuticals Pvt. Ltd.
- Mylan Specialty LP
- Mylan Technologies Inc.
- Penederm Inc.
- Somerset Pharmaceuticals Inc.
- Senior Management
-
Heather Bresch, CEO
Ken D Parks, CFO
Anthony Mauro, Chief Commercial Officer - Contact Info
-
Mylan NV
Phone: 1707 853000
Bldg. 4, Trident Pl.
Mosquito Way
Hatfield, PA AL10 9UL
UK
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice